Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced DehydraTECH Delivers More CBD into the Body

• The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets
• DehydraTECH has demonstrated that it can deliver eight times more CBD into the blood than standard industry formulations
• Animal testing shows that combining DehydraTECH with a nanoemulsion formulation greatly assists delivery of cannabinoids and nicotine across the blood-brain barrier

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new enhanced version of its patented delivery technology, DehydraTECH, has demonstrated that it can deliver eight-times more CBD into the blood and 19-times more CBD into the brain tissue than standard industry formulations. These results were confirmed in clinical lab tests conducted with live animals. LXRP has filed new patent applications based on these innovations (http://nnw.fm/bXV3l).

The new DehydraTECH delivery platform is ideally suited for solid-oral dosage forms such as capsules, pills and tablets for use by the pharmaceutical, medical and supplement markets.

LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees.

In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137 percent more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://nnw.fm/SU1sL). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.

In animal tests conducted in 2018 and 2019, results showed that DehydraTECH greatly assisted in the delivery of drugs, including nicotine and cannabinoids, across the blood-brain barrier. The demonstrated effectiveness of DehydraTECH, combined with nanoemulsification, significantly expands the application of the technology for conventional dosage forms, consumable liquids and beverage dosage forms.

LXRP is a Canadian bioscience company and a drug-delivery platform innovator. The company out-licenses its disruptive delivery technology, DehydraTECH. The technology is designed to promote healthier ingestion methods and lower overall dosing. Lexaria is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and has multiple patents pending in more than 40 countries worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com